MX347229B - Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. - Google Patents

Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.

Info

Publication number
MX347229B
MX347229B MX2014008960A MX2014008960A MX347229B MX 347229 B MX347229 B MX 347229B MX 2014008960 A MX2014008960 A MX 2014008960A MX 2014008960 A MX2014008960 A MX 2014008960A MX 347229 B MX347229 B MX 347229B
Authority
MX
Mexico
Prior art keywords
peptide
terminal fragment
calcitonin gene
modified calcitonin
amino acid
Prior art date
Application number
MX2014008960A
Other languages
English (en)
Other versions
MX2014008960A (es
Inventor
Christopher J Soares
Original Assignee
Christopher J Soares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher J Soares filed Critical Christopher J Soares
Publication of MX2014008960A publication Critical patent/MX2014008960A/es
Publication of MX347229B publication Critical patent/MX347229B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a las modalidades proporcionan un antagonista del péptido relacionado con el gen de calcitonina modificado que incluye un fragmento N terminal de un péptido relacionado con el gen de calcitonina modificado o un miembro de la familia de proteína relacionado en donde al menos dos residuos del fragmento N terminal son cisteína (Cys) y al menos un aminoácido comprende una sustitución no de treonina de un residuo de treonina (Thr); un núcleo central en donde el núcleo central comprende una hélice a; y un fragmento C terminal del péptido relacionado con el gen de calcitonina modificado o un miembro de la familia de proteína relacionado que comprende una amida C terminal y en donde al menos un aminoácido del fragmento C terminal es fenilalanina (Phe), prolina (Pro), tirosina (Tyr) o hidroxiprolina (Hyp) o una sal farmacéuticamente aceptable del mismo, así como composiciones, incluyendo composiciones farmacéuticas, que comprenden el péptido en cuestión. Las modalidades proporcionan además métodos de tratamientos que incluyen métodos para tratar una migraña, implicando en general los métodos la administración a un individuo que lo necesita de una cantidad efectiva de un péptido o la composición en cuestión.
MX2014008960A 2012-01-26 2013-01-25 Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. MX347229B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591236P 2012-01-26 2012-01-26
PCT/US2013/023260 WO2013112912A1 (en) 2012-01-26 2013-01-25 Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Publications (2)

Publication Number Publication Date
MX2014008960A MX2014008960A (es) 2015-01-16
MX347229B true MX347229B (es) 2017-04-19

Family

ID=47682066

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008960A MX347229B (es) 2012-01-26 2013-01-25 Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.

Country Status (15)

Country Link
US (3) US9193776B2 (es)
EP (2) EP3272769B1 (es)
JP (3) JP6025871B2 (es)
KR (2) KR102052983B1 (es)
CN (2) CN104271596B (es)
AU (2) AU2013211929B2 (es)
CA (1) CA2861392C (es)
DK (1) DK2807187T3 (es)
ES (2) ES2641325T3 (es)
HK (2) HK1201068A1 (es)
IL (2) IL233655A (es)
MX (1) MX347229B (es)
NO (1) NO2864579T3 (es)
RU (2) RU2624016C2 (es)
WO (1) WO2013112912A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641325T3 (es) * 2012-01-26 2017-11-08 Christopher J. Soares Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso
EP3027644B1 (en) * 2013-07-30 2019-08-21 Christopher J. Soares Cgrp agonist peptides
JO3669B1 (ar) 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
CN116063580A (zh) * 2016-01-04 2023-05-05 艾得佩索拉公司 肽类似物
US11390654B2 (en) 2016-09-02 2022-07-19 Christopher Joseph Soares Use of CGRP receptor antagonists in neuroprotection and neurological disorders
CA2967616A1 (en) * 2016-09-19 2018-03-19 The Governors Of The University Of Alberta Brain penetrant amylin receptor based peptides for alzheimer's disease
AU2018362018A1 (en) * 2017-11-06 2020-06-25 Auckland Uniservices Limited Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof
JP7214104B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4530838A (en) 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
JPS62231168A (ja) 1986-03-21 1987-10-09 ハイブリテツク・インコ−ポレイテツド アナライト−レセプタ−分析用内部標準を設けるための改良法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
PT644771E (pt) 1992-06-11 2002-12-31 Alkermes Inc Sistema de entrega da droga eritropoietina
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU6524794A (en) 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP2008500281A (ja) * 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
WO2007055728A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CN101208098A (zh) * 2005-03-31 2008-06-25 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
KR101383493B1 (ko) * 2005-03-31 2014-04-11 아스트라제네카 파마수티컬스 엘피 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및아밀린 효능제
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
ES2433251T5 (es) * 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
US20100323955A1 (en) 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
US20140249076A1 (en) 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
ES2641325T3 (es) * 2012-01-26 2017-11-08 Christopher J. Soares Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso
RS59295B1 (sr) 2012-02-27 2019-10-31 Bristol Myers Squibb Co N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat so

Also Published As

Publication number Publication date
KR102052983B1 (ko) 2019-12-06
WO2013112912A1 (en) 2013-08-01
IL252555A0 (en) 2017-07-31
JP2017036308A (ja) 2017-02-16
ES2641325T3 (es) 2017-11-08
CA2861392A1 (en) 2013-08-01
HK1201068A1 (en) 2015-08-21
ES2819825T3 (es) 2021-04-19
EP2807187A1 (en) 2014-12-03
JP2019006821A (ja) 2019-01-17
RU2017119773A (ru) 2018-12-06
KR20140132342A (ko) 2014-11-17
NO2864579T3 (es) 2018-01-20
KR20170071613A (ko) 2017-06-23
CN104271596B (zh) 2018-09-18
US10370425B2 (en) 2019-08-06
CN104271596A (zh) 2015-01-07
RU2742826C2 (ru) 2021-02-11
CA2861392C (en) 2021-08-17
JP6411425B2 (ja) 2018-10-24
IL252555B (en) 2020-06-30
AU2013211929A1 (en) 2014-09-11
US20140329752A1 (en) 2014-11-06
EP2807187B1 (en) 2017-07-26
AU2016205801A1 (en) 2016-08-04
MX2014008960A (es) 2015-01-16
EP3272769B1 (en) 2020-06-17
AU2013211929B2 (en) 2016-05-26
HK1249915A1 (zh) 2018-11-16
CN108997490A (zh) 2018-12-14
RU2624016C2 (ru) 2017-06-30
KR101855242B1 (ko) 2018-05-09
IL233655A (en) 2017-06-29
JP6025871B2 (ja) 2016-11-16
EP3272769A1 (en) 2018-01-24
JP2015513318A (ja) 2015-05-07
RU2017119773A3 (es) 2020-11-18
US20160145315A1 (en) 2016-05-26
DK2807187T3 (en) 2017-09-11
BR112014018284A2 (pt) 2017-07-04
RU2014131605A (ru) 2016-03-20
IL233655A0 (en) 2014-08-31
US9193776B2 (en) 2015-11-24
US20170204155A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
MX347229B (es) Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
PH12020551066A1 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
MX2018013622A (es) Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
BR112018076437A2 (pt) interferon porcino peguilado e seus métodos de utilização
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EA201170337A1 (ru) Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
MX345501B (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
GT200900304A (es) "antagonistas ciclicos de peptido cxcr4"
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
IN2012DN06437A (es)
AR096162A1 (es) Péptidos terapéuticos
MY194925A (en) Composition of fish skin collagen peptides and use thereof as a drug
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
GT201700224A (es) Proteína de unión a rgma y su uso
AR078445A1 (es) Agonistas del peptido natriuretico tipo b (npr -b)
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
JP2015513318A5 (es)
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
CL2012001656A1 (es) Polipéptido de somatotropina bovina que comprende uno o mas aminoácidos no naturales y que estan ligados a un polimero soluble en agua. composicion farmaceutica que comprende dichos polipeptidos.
NI201200085A (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina

Legal Events

Date Code Title Description
FG Grant or registration